BIOCRYST PHARMACEUTICALS, INC. Restricted Cash and Cash Equivalents, Current
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Restricted Cash and Cash Equivalents, Current of $479.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue · last filed 2026-08-05
- 2026-06-30: Restricted Cash and Cash Equivalents, Current $479.00K.
- 2026-03-31: Restricted Cash and Cash Equivalents, Current $854.00K.
- 2025-12-31: Restricted Cash and Cash Equivalents, Current $201.00K.
- 2025-09-30: Restricted Cash and Cash Equivalents, Current $579.00K.
| Period end | Restricted Cash and Cash Equivalents, Current |
|---|---|
| 2026-06-30 | $479.00K 10-Q · filed 2026-08-05 |
| 2026-03-31 | $854.00K 10-Q · filed 2026-05-06 |
| 2025-12-31 | $201.00K 10-Q · filed 2026-08-05 |
| 2025-09-30 | $579.00K 10-Q · filed 2025-11-04 |
| 2025-06-30 | $492.00K 10-Q · filed 2026-08-05 |
| 2025-03-31 | $291.00K 10-Q · filed 2026-05-06 |
| 2024-12-31 | $210.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $813.00K 10-Q · filed 2025-11-04 |
| 2024-06-30 | $1.79M 10-Q · filed 2025-08-05 |
| 2024-03-31 | $1.80M 10-Q · filed 2025-05-06 |
| 2023-12-31 | $1.80M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.58M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $1.57M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $1.46M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $1.47M 10-K · filed 2025-02-25 |
| 2022-09-30 | $1.44M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $1.45M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $3.35M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $3.35M 10-K · filed 2023-02-27 |
| 2021-09-30 | $4.30M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $4.35M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $4.01M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $2.22M 10-K · filed 2022-02-28 |
| 2020-09-30 | $2.21M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $2.19M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $1.56M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $1.55M 10-K · filed 2021-03-01 |
| 2019-09-30 | $1.55M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $4.63M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $2.39M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $1.54M 10-K · filed 2020-03-13 |
| 2018-09-30 | $1.51M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $7.63M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $4.60M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $3.29M 10-K · filed 2019-03-14 |
| 2017-09-30 | $3.12M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $5.36M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $2.80M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $1.55M 10-K · filed 2018-03-12 |
| 2016-09-30 | $1.51M 10-Q · filed 2016-11-08 |
| 2016-06-30 | $4.43M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $1.97M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $1.61M 10-K · filed 2017-02-27 |
| 2015-09-30 | $1.62M 10-Q · filed 2015-11-06 |
| 2015-06-30 | $1.57M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $2.64M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $150.00K 10-K · filed 2016-02-26 |
| 2014-09-30 | $150.00K 10-Q · filed 2014-11-07 |
| 2014-06-30 | $150.00K 10-Q · filed 2014-08-08 |
| 2014-03-31 | $150.00K 10-Q · filed 2014-05-09 |
| 2013-12-31 | $151.00K 10-K · filed 2015-03-02 |
| 2013-09-30 | $150.00K 10-Q · filed 2013-11-08 |
| 2013-06-30 | $2.13M 10-Q · filed 2013-08-08 |
| 2013-03-31 | $616.00K 10-Q · filed 2013-05-09 |
| 2012-12-31 | $308.00K 10-K · filed 2014-03-10 |
| 2012-09-30 | $300.00K 10-Q · filed 2012-11-08 |
| 2012-06-30 | $2.23M 10-Q · filed 2012-08-08 |
| 2012-03-31 | $955.00K 10-Q · filed 2012-05-08 |
| 2011-12-31 | $625.00K 10-K · filed 2013-03-11 |
| 2011-09-30 | $625.00K 10-Q · filed 2011-11-03 |
| 2011-06-30 | $1.42M 10-Q · filed 2011-08-04 |
| 2010-12-31 | $625.00K 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |